Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-Current Debt (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Non-Current Debt for 5 consecutive years, with $100.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 6.81% to $100.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $100.9 million through Dec 2025, down 6.81% year-over-year, with the annual reading at $100.9 million for FY2025, 6.81% down from the prior year.
  • Non-Current Debt for Q4 2025 was $100.9 million at Rhythm Pharmaceuticals, down from $103.4 million in the prior quarter.
  • The five-year high for Non-Current Debt was $108.3 million in Q4 2024, with the low at $100.9 million in Q4 2025.
  • Average Non-Current Debt over 3 years is $105.4 million, with a median of $106.1 million recorded in 2023.
  • The sharpest move saw Non-Current Debt increased 2.0% in 2024, then dropped 6.81% in 2025.
  • Over 3 years, Non-Current Debt stood at $106.1 million in 2023, then increased by 2.0% to $108.3 million in 2024, then decreased by 6.81% to $100.9 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $100.9 million, $103.4 million, and $106.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.